Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau pSer396 and pSer404 Define Distinct Epitope Regions Linked to Different Antibody Functions.

bioRxiv : the preprint server for biology·2026
Same author

Autophagosome-targeting single-domain antibody clears tau in patient-derived neurons and improves motor function in tauopathy mice.

Science translational medicine·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice.

Cell reports·2025
Same author

Single-Domain Antibody-Based Autophagosome-Targeting Chimera for Tau Clearance and Motor Function Restoration in Tauopathies.

bioRxiv : the preprint server for biology·2025
Same journal

Gut microbiota alterations in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2026
Same journal

Stage-dependent relationship between sleep duration and cortical tau deposition in cognitively impaired individuals: A cross-sectional study.

Journal of Alzheimer's disease : JAD·2026
Same journal

Multilayer brain connectivity and long-term cognitive changes in individuals at risk for Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same journal

The creation and verification of a detection model for mild cognitive impairment by employing eye-tracking and gait metrics.

Journal of Alzheimer's disease : JAD·2026
Same journal

Compartment-specific analysis reveals disrupted astrocytic calcium transients in anesthetized Alzheimer's disease mice.

Journal of Alzheimer's disease : JAD·2026
Same journal

<i>APOE</i> ε4-specific associations between agitation, cerebrospinal fluid biomarkers, and cognitive decline in cognitively impaired patients.

Journal of Alzheimer's disease : JAD·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

Is tau aggregation toxic or protective?

Erin E Congdon1, Karen E Duff

  • 1Taub Institute for Research on Alzheimer's Disease, Department of Pathology, Columbia University, New York, NY, USA.

Journal of Alzheimer'S Disease : JAD
|August 9, 2008
PubMed
Summary
This summary is machine-generated.

This review examines the toxicity of different forms of tau protein in Alzheimer's disease. It investigates whether tau filaments, monomers, or smaller aggregates are the primary drivers of neurodegeneration.

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Abnormal protein deposits, like tau tangles, are hallmarks of Alzheimer's disease (AD).
  • Tau pathology correlates with neuronal death and disease severity in AD.
  • The precise role of different tau species in AD pathogenesis is debated.

Purpose of the Study:

  • To review and analyze the existing research on the toxicity of various tau species in Alzheimer's disease.
  • To clarify whether tau monomers, oligomers, or larger filaments are the primary toxic agents.
  • To discuss the implications for understanding disease mechanisms and potential therapeutic strategies.

Main Methods:

  • Literature review of cell and animal models investigating tau toxicity.
  • Analysis of studies differentiating the effects of monomeric, oligomeric, and fibrillar tau.
  • Synthesis of conflicting findings regarding the pathogenic role of distinct tau species.

Main Results:

  • Conflicting evidence exists regarding the relative toxicity of different tau species.
  • Some studies suggest smaller, soluble tau species (monomers or oligomers) are most toxic.
  • Other findings indicate larger tau filaments may also contribute to or be a consequence of toxicity.

Conclusions:

  • The exact toxic tau species in Alzheimer's disease remains controversial.
  • Understanding the specific toxic species is crucial for developing targeted AD therapies.
  • Further research is needed to definitively establish the role of each tau form in neurodegeneration.